Medical Condition News

RSS

KU professor to create patient-friendly lung cancer treatment

A Kansas State University professor is trying to create a patient-friendly treatment to help the more than 220,000 people who are diagnosed with lung cancer each year.

23 Aug 2011

Pear, VeraLight partner to distribute SCOUT DS device in pharmacies across Canada

VeraLight Inc., the first company to develop an optical skin measurement for noninvasive diabetes screening, and Pear Healthcare Solutions Inc., a leading provider of in-pharmacy health screening and education services, today announced an agreement for the distribution of the SCOUT DS device in pharmacies across Canada.

23 Aug 2011

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer.

23 Aug 2011

High-salt diets with low physical activity can impact brain health in older adults

Older adults who lead sedentary lifestyles and consume a lot of sodium in their diet may be putting themselves at risk for more than just heart disease.

23 Aug 2011

itm FlowMedical initiates Rhenium-PTA therapy clinical trial in PAOD

itm FlowMedical GmbH announced the start of OPEN-188 clinical trial. It will compare itm Rhenium-PTA, a therapy for the prevention of restenosis in peripheral vessels, to a regular PTA, the standard therapy for the treatment of PAOD.

23 Aug 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

Study: More attention needs to be paid for cartilage during RA diagnosis

This could lead to a paradigm shift in the treatment of rheumatoid arthritis: rheumatologists at the Medical University of Vienna have discovered, through a secondary study involving 3,000 female patients, that the condition of the cartilage in inflammatory joint rheumatism needs to be paid more attention than has previously been the case. Until now, the focus lay mainly on investigating the damage to the bone.

23 Aug 2011

OICR President announces $12.6M in funding for High Impact Clinical Trials Program

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), today announced $12.6 million in funding over four years for OICR's High Impact Clinical Trials (HICT) Program.

23 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Radium-223 chloride granted FDA Fast Track designation for treatment of CRPC

Algeta ASA, a company focused on the development of novel targeted cancer therapeutics, today announced that radium-223 chloride has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant (hormone refractory) prostate cancer in patients with bone metastases.

23 Aug 2011

Survival for patients with HCC increases with radioembolization

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is likely to provide survival benefit across different tumor stages, including patients with advanced liver cancer and with limited treatment options.

23 Aug 2011

Phadia launches new allergy and autoimmunity testing instruments

Today Phadia, the global leader in allergy and autoimmune related diseases diagnostics, announced the launch of Phadia's new allergy and autoimmunity testing instruments; Phadia 2500 and Phadia 5000.

23 Aug 2011

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.

23 Aug 2011

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

IsoRay, Inc. said today that a growing number of hospitals and medical treatment centers are adopting its proprietary mesh Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) for use in conjunction with the da Vinci® Surgical System to treat early stage lung cancer patients. One of the most recent adopters is Georgia's Archbold Memorial Hospital.

23 Aug 2011

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

Working closely with a team of researchers from Duke University, scientists from the Florida campus of The Scripps Research Institute have helped identify a molecular pathway that plays a key role in stress-related damage to the genome, the entirety of an organism's hereditary information.

23 Aug 2011

CTI responds to EMA's Day 120 letter for pixantrone MAA

Cell Therapeutics, Inc. today announced that it has submitted its response to the Day 120 List of Outstanding Issues to the European Medicines Agency's Committee for Medicinal Products for Human Use in regards to CTI's Marketing Authorization Application for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Aug 2011

Stem cells of oral mucosa stay young, says Tel Aviv University researcher

While highly potent embryonic stem cells are often the subject of ethical and safety controversy, adult-derived stem cells have other problems. As we age, our stem cells are less pliant and less able to transform into the stem cells that science needs to find breakthrough treatments for disease.

23 Aug 2011

DMS receives NIH grant to establish Center of Biomedical Research Excellence

Under an $11-million grant from the National Institutes of Health (NIH), Dartmouth Medical School (DMS) will lead a network of northern New England institutions in recruiting, training, and supporting young quantitative biologists to teach and conduct research into the ways that genes and the environment work together to trigger and prevent disease.

23 Aug 2011

Almost all heart attack patients receive angioplasty within 90 minutes of being admitted

Almost all heart attack patients who need the emergency artery-opening procedure known as angioplasty are receiving it within 90 minutes of being admitted to the hospital, a marked improvement from five years ago when most patients waited longer for the life-saving procedure, according to a report by Yale School of Medicine researchers and their colleagues.

23 Aug 2011

New research reveals stubbornly low public awareness of bowel cancer

BRITONS have very low awareness of the signs and symptoms of bowel cancer - the third most common cancer in the UK and second largest cause of cancer deaths each year, new research shows.

23 Aug 2011

Medical Condition News

KU professor to create patient-friendly lung cancer treatment

Pear, VeraLight partner to distribute SCOUT DS device in pharmacies across Canada

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

High-salt diets with low physical activity can impact brain health in older adults

itm FlowMedical initiates Rhenium-PTA therapy clinical trial in PAOD

Spinifex secures AU$6.25 million in expanded Series B funding

Study: More attention needs to be paid for cartilage during RA diagnosis

OICR President announces $12.6M in funding for High Impact Clinical Trials Program

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Radium-223 chloride granted FDA Fast Track designation for treatment of CRPC

Survival for patients with HCC increases with radioembolization

Phadia launches new allergy and autoimmunity testing instruments

Santarus, Depomed enter new commercialization agreement for GLUMETZA

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

CTI responds to EMA's Day 120 letter for pixantrone MAA

Stem cells of oral mucosa stay young, says Tel Aviv University researcher

DMS receives NIH grant to establish Center of Biomedical Research Excellence

Almost all heart attack patients receive angioplasty within 90 minutes of being admitted

New research reveals stubbornly low public awareness of bowel cancer

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News